NSE filing, NSE: SAMBHV. Summary written from the filing by ALFA Finder's alert engine.
Sambhv Steel Tubes Ltd: key numbers
- Share price
- ₹163.90
- Market cap
- ₹4,830 Cr
- Revenue (annual)
- ₹2,413 Cr
- Net profit (annual)
- ₹142.2 Cr
- P/E (TTM)
- 24.8×Sector 17.2×
- Promoter holding
- 56.11%+0.00% QoQ
- FII holding
- 1.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sambhv Steel Tubes Ltd
All →Sambhv Steel Tubes Capacity Expansion: ₹148 Cr Investment
Sambhv Steel Tubes approved a Rs 148 Crore project adding 14,400 MTPA of stainless steel seamless pipe capacity. Funding comes from debt and internal accruals.
- Value
- ₹148.0 Cr
- Stainless steel seamless pipes and tubes capacity
- 14400.0 MTPA
Sambhv Steel Tubes Business Update
Sambhv Steel Tubes executed a five-year services agreement with Sachin Tendulkar for endorsement and marketing of its steel products under the 'Sambhv' brand. The agreement takes effect from December 07, 2026, and no monetary value is disclosed.
- Execution
- 5 years from December 07, 2026
Sambhv Steel Tubes Earnings Call Transcript: Key Takeaways
Management focused on volume growth in structural pipes despite margin compression from Chinese dumping and monsoon impacts.
Sambhv Steel Tubes Investor Presentation: Key Takeaways
Q2FY27 standalone revenue Rs836 Cr (+44% YoY), PAT Rs61 Cr (+104%), Op. EBITDA Rs101 Cr (+68%). Vision 2030 targets over 2 MMTPA finished capacity.
Sambhv Steel Tubes Q2 FY27 Results: Net Profit ₹60.9 Cr, Up 99.0% YoY
Sambhv Steel Tubes Ltd reported revenue from operations of ₹836 Cr (+44.1% YoY) and net profit of ₹60.9 Cr (+99.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹60.9 Cr · +99.0% YoY
Sambhv Steel Tubes Board Meeting Date
Sambhv Steel Tubes will hold a board meeting on 29 October 2026 to consider unaudited quarterly results for September 2026. The trading window stays closed until 31 October 2026.
Other regulatory approval announcements
All →Arihant Capital Markets Regulatory Approval
Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.
Dr. Reddy's Laboratories Regulatory Approval
Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.
Emmbi Industries Regulatory Approval
SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.
Bliss GVS Pharma Regulatory Approval
Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.
John Cockerill India Regulatory Approval
John Cockerill India received Reserve Bank of India approval for acquiring shares of John Cockerill Metals International SA. This allows the company to proceed with the share-swap acquisition.